Management of hyperlipidemia in older adults

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 14, Issue 1, 2009, Pages 49-58

  Alexander, Karen P ^a,f   Blazing, Michael A ^a   Rosenson, Robert S ^b   Hazard, Elisabeth ^c   Aronow, Wilbert S ^d   Smith Jr , Sidney C ^e   Ohman, E Magnus ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c ValueMedics Research LLC   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Cardiovascular disease; Elderly; Low density lipoprotein cholesterol; Statins

Indexed keywords

AMIODARONE; ATORVASTATIN; CERIVASTATIN; CIMETIDINE; CLARITHROMYCIN; CREATINE KINASE; CYCLOSPORIN; DILTIAZEM; ERYTHROMYCIN; EZETIMIBE PLUS SIMVASTATIN; FLUCONAZOLE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; OMEPRAZOLE; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; VERAPAMIL;

CLINICAL TRIAL; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; DRUG FATALITY; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; MORTALITY; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; MYALGIA; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; TREATMENT RESPONSE;

AGE FACTORS; AGED; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPIDS; MALE; MEDICATION ADHERENCE; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; TREATMENT OUTCOME;

EID: 61449115898     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248408328927     Document Type: Review

References (54)

1. Thom T., Haase N., Rosamond W., et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006; 113: e85 - e151.
2. Heiss G., Tamir I., Davis CE, et al. Lipoprotein-cholesterol distributions in selected North American populations: the lipid research clinics program prevalence study. Circulation. 1980; 61: 302-315.
3. DeWilde S., Carey IM, Bremner SA, Richards N., Hilton SR, Cook DG Evolution of statin prescribing 1994-2001: a case of agism but not of sexism ? Heart. 2003; 89: 417-421.
4. Ko DT, Mamdani M., Alter DA Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA. 2004; 291: 1864-1870.
5. Alexander KP, Roe MT, Chen AY, et al. CRUSADE Investigators. Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol. 2005; 46: 1479-1487.
6. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486-2497.
7. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110: 227-239.
8. Williams MA, Fleg JL, Ades PA, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients > or =75 years of age): an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation. 2002; 105: 1735-1743.
9. LaRosa JC, Grundy SM, Waters DD, et al. for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352: 1425-1435.
10. Smith SC Jr, Allen J., Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006; 113: 2363-2372.
11. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 1383-1389.
12. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998; 339: 1349-1357.
13. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335: 1001-1009.
14. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360: 7-22.
15. Sever PS, Dahlof B., Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomised controlled trials. Lancet. 2003; 361: 1149-1158.
16. Shepherd J., Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002; 360: 1623-1630.
17. Collins R., Armitage J. High-risk elderly patients PROSPER from cholesterol-lowering therapy. Lancet. 2002; 360: 1618-1619.
18. Deedwania P., Stone PH, Bairey Merz CN, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation. 2007; 115: 700-707.
19. Wenger NK, Lewis SJ, Herrington DM, Bittner V., Welty FK Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med. 2007; 147: 1-9.
20. Ray KK, Bach RG, Cannon CP, et al. and PROVE IT-TIMI 22 Investigators. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. Eur Heart J. 2006; 27: 2310-2316.
21. Shepherd J., Cobbe SM, Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333: 1301-1307.
22. Miettinen TA, Pyörälä K., Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation. 1997; 96: 4211-4218.
23. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med. 1998; 129: 681-689.
24. Hunt D., Young P., Simes J., et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med. 2001; 134: 931-940.
25. Sacks FM, Tonkin AM, Shepherd J., et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation. 2000; 102: 1893-1900.
26. Roberts CG, Guallar E., Rodriguez A. Efficacy and safety of statin monotherapy in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci. 2007; 62: 879-887.
27. Afilalo J., Duque G., Steele R., Jukema JW, Craen AJ, Eisenberg MJ Statins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analysis. J Am Coll Cardiol. 2008; 51: 37-45.
28. Downs JR, Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998; 279: 1615-1622.
29. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/ AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002; 40: 567-572.
30. Einarson TR, Metge CJ, Iskedjian M., Mukherjee J. An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutaryl-coenzyme A reductase inhibitors on health care utilization: a Canadian population-based study. Clin Ther. 2002; 24: 2126-2136.
31. Buettner C., Davis RB, Leveille SG, Mittleman MA, Mukamal KJ Prevalence of musculoskeletal pain and statin use. J Gen Intern Med. 2008; 23: 1182-1186.
32. Phillips PS, Haas RH, Bannykh S., et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002; 137: 581-585.
33. Agostini JV, Tinetti ME, Han L., McAvay G., Foody JM, Concato J. Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults. J Am Geriatr Soc. 2007; 55: 420-425.
34. Jacobson TA The safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered ? Mayo Clin Proc. 2006; 81: 1225-1231.
35. Bruckert E., Hayem G., Dejager S., Yau C., Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther. 2005; 19: 403-414.
36. Pfeffer MA, Keech A., Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation. 2002 ; 105: 2341-2346.
37. Law M., Rudnicka AR Statin safety: a systematic review. Am J Cardiol. 2006; 97: 52C - 60C.
38. Opie LH, Commerford PJ, Gersh BJ Controversies in stable coronary artery disease. Lancet. 2006; 367: 69-78.
39. Baigent C., Keech A., Kearney PM, et al. and Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366: 1267-1278.
40. McKenney JM, Davidson MH, Jacobson TA, Guyton JR Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006; 97: 89C - 94C.
41. O'Keefe JH Jr, Cordain L., Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004; 43: 2142-2146.
42. Pearson TA, Laurora I., Chu H., Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000; 160: 459-467.
43. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006; 166: 1842-1847.
44. Benner JS, Glynn RJ, Mogun H., Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002; 288: 455-461.
45. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006; 113: 203-212.
46. Rasmussen JN, Chong A., Alter DA Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007; 297: 177-186.
47. Eagle KA, Kline-Rogers E., Goodman SG, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med. 2004; 117: 73-81.
48. Spertus JA, Kettelkamp R., Vance C., et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006; 113: 2803-2809.
49. Brenner S. Antioxidants and risk of Alzheimer disease. JAMA. 2002; 288: 2265.
50. Kaufman DW, Kelly JP, Rosenberg L., Anderson TE, Mitchell AA Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002; 287: 337-344.
51. Moxey ED, O'Connor JP, Novielli KD, Teutsch S., Nash DB Prescription drug use in the elderly: a descriptive analysis. Health Care Financ Rev. 2003; 24: 127-141.
52. Federman AD, Adams AS, Ross-Degnan D., Soumerai SB, Ayanian JZ Supplemental insurance and use of effective cardiovascular drugs among elderly Medicare beneficiaries with coronary heart disease. JAMA. 2001; 286: 1732-1739.
53. Jackevicius CA, Mamdani M., Tu JV Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002; 288: 462-467.
54. Jackevicius CA, Li P., Tu JV Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation. 2008; 117: 1028-1036.